Related Experiment Videos
Improving vaccine supply and development: who needs what?
1University of Pennsylvania, Philadelphia, PA, USA. pauly@wharton.upenn.edu
Health Affairs (Project Hope)
|May 12, 2005
Summary
Inadequate vaccine payments have led to shortages. Undervaluation by payers and consumers, alongside low profitability, discourages vaccine development and supply.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Vaccinology
Background:
- Recent vaccine shortages suggest payment structures may be insufficient.
- Stakeholder roles in vaccine pricing and supply chain stability require examination.
Purpose of the Study:
- To analyze the influence of various stakeholders on current vaccine payment levels.
- To identify factors contributing to potential increases in vaccine reimbursement.
- To explore the economic disincentives affecting vaccine development and production.
Main Methods:
- Qualitative analysis of payment mechanisms.
- Stakeholder role assessment in pricing negotiations.
- Economic modeling of vaccine market incentives.
Main Results:
- Evidence suggests undervaluation of vaccines by government payers, private insurers, and consumers.
- Limited profitability in vaccine markets may divert resources from new vaccine development.
- Insufficient producer incentives exist to maintain adequate vaccine supply and prevent disruptions.
Conclusions:
- Inadequate reimbursement is a key driver of vaccine shortages.
- Revising payment structures is crucial for ensuring vaccine supply security.
- Addressing economic undervaluation is necessary to incentivize vaccine innovation and production.